Mice receiving the combination of CAR T cells+dex+IL-7, but not the CAR+IL-7 group, had circulating human T cells on day 25 (Figure 6B), which corresponded with a significantly lower tumor burden over time (Figure 6C). Here, IL7 is linked to neoplasm.